



Press Release

8 December 2006

Novo Nordisk realises capital gain from sale of venture investment in Domantis Ltd

Today, GlaxoSmithKline (GSK) announced that it has entered into an agreement to acquire the British biotech company Domantis Ltd for GBP 230 million in cash.

Novo Nordisk has been a minority shareholder in Domantis Ltd since December 2005 following an equity investment made by Novo Nordisk's Biotech Fund, which is the company's internal biotech venture fund.

The fund focuses on venture investments in promising biotech companies that hold the potential to influence the future of the pharmaceutical industry by means of pioneering technologies and competencies.

Novo Nordisk expects to realise a pre-tax capital gain of around DKK 100 million for 2006 as a consequence of the divestment.

GSK's acquisition of Domantis Ltd is subject to customary clearance under the United States Hart-Scott-Rodino Antitrust Improvements Act.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,000 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

For further information please contact:

Media:

Outside North America:

Mike Rulis

Tel: (+45) 4442 3573

mike@novonordisk.com

Investors:

Outside North America:

Mogens Thorsager Jensen

Tel: (+45) 4442 7945

mtj@novonordisk.com

Christian Qvist Frandsen

Tel: (+45) 4443 5182

cqfr@novonordisk.com

Hans Rommer

Tel: (+45) 4442 4765

hrrm@novonordisk.com

In North America:

Susan T Jackson

Tel: (+1) 609 919 7776

stja@novonordisk.com

In North America:

Mads Veggerby Lausten

Tel: (+1) 609 919 7937

mlau@novonordisk.com